Teva提交FDA申请使用医疗细胞技术每月注射精神分裂症治疗。 Teva submits FDA application for monthly injectable schizophrenia treatment using Medincell's technology.

采用Medincell的技术,Teva制药公司已向FDA提交了一份关于TEV-749的新药申请,该药是一种每月注射一次的成年精神分裂症治疗兰扎. Teva Pharmaceuticals, with Medincell's technology, has submitted a New Drug Application to the FDA for TEV-‘749, a once-monthly injectable olanzapine treatment for adult schizophrenia. 这项应用基于SOLARIS第三阶段试验,使用SteadyTeqTM共聚物技术进行持续释放. The application, based on the phase 3 SOLARIS trial, uses SteadyTeq™ copolymer technology for sustained release. 其目的是通过以每月注射取代每天服用的药丸,解决精神分裂症护理方面的重大差距,从而改善坚持性和稳定性。 It aims to improve adherence and stability by replacing daily pills with a monthly injection, addressing a major gap in schizophrenia care. 美国食品和药物管理局将审查申请以确定批准. The FDA will review the application to determine approval.